Insmed (INSM) | Stock Overview & Key Data
Insmed Performance Comparison
Stock Range
Today's Range
Low: $107.07
High: $109.88
on August 8, 2025
52 Week Range
Low: $60.40
High: $113.10
on April 9, 2025
on August 5, 2025
All-Time High: $199.38 on August 28, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$21.1B
EPS
-5.93
P/E Ratio (TTM)
N/A
Forward P/E
-26.30
P/B Ratio
204.11
PEG Ratio
-26.30
Div. Yield
N/A
ROE
-320.20%
Beta
0.946
Debt to Equity
1,316.96
Financial Highlights
Profitability
Gross Margin
77.08%
Operating Margin
-247.61%
Profit Margin
-265.93%
Returns and Earnings
Return on Assets (TTM)
-36.25%
Return on Equity (TTM)
-320.20%
EBITDA
$-849.8M
Net Income (TTM)
$-1.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$2.12
Quarterly Revenue Growth (YoY)
22.90%
Quarterly Earnings Growth (YoY)
22.94%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Insmed INSM | 21.13B Large-cap | 1.88% | 12.74% | 60.08% | 36.71% | 56.25% | 50.39% | 308.14% | 317.96% |
| Vertex VRTX | 121.28B Large-cap | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% | -17.68% | 30.94% | 44.28% |
| Regeneron REGN | 60.39B Large-cap | 2.63% | 4.03% | -0.20% | -21.15% | -21.73% | -50.93% | -11.70% | -9.38% |
| Alnylam ALNY | 56.22B Large-cap | 10.93% | 34.24% | 57.33% | 57.54% | 86.24% | 61.48% | 86.11% | 219.69% |
| Royalty Pharma plc RPRX | 21.19B Large-cap | 0.57% | 3.99% | 13.01% | 16.64% | 43.51% | 41.36% | -16.02% | -18.26% |
| Incyte INCY | 15.24B Large-cap | 4.42% | 16.25% | 31.32% | 5.49% | 12.47% | 27.13% | 4.95% | -18.15% |
Ownership & Short Interest
Insider Ownership
0.75%
Institutional Ownership
109.87%
Shares Short
10M
Short Ratio
2.00
Short % of Shares Outstanding
5.72%
Average 10-Day Volume
2M
Average 90-Day Volume
4M
Insmed Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Insmed would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is INSM's 52-week high and low?
- In the last 52 weeks, Insmed reached a high of $113.10 (on August 5, 2025) and a low of $60.40 (on April 9, 2025).
- What is the market cap and P/E ratio for INSM?
- Curious about Insmed's size and valuation? Its market capitalization stands at 21.13B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -26.30.
- Does INSM pay dividends? If so, what's the yield?
- As for dividends, Insmed isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Insmed's main competitors or similar companies to consider before investing?
When looking at Insmed, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -17.68% 30.94% Regeneron
REGN60.39B Healthcare Biotechnology -50.93% -11.70% Alnylam
ALNY56.22B Healthcare Biotechnology 61.48% 86.11% Royalty Pharma plc
RPRX21.19B Healthcare Biotechnology 41.36% -16.02% Incyte
INCY15.24B Healthcare Biotechnology 27.13% 4.95% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Insmed Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Insmed's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -320.20%, the Debt to Equity ratio from the most recent quarter is 1,316.96, and its Gross Profit Margin stands at 77.08%.
- What is the recent revenue and earnings growth for INSM?
- Looking at Insmed's growth, its revenue over the trailing twelve months (TTM) was $381M. Compared to the same quarter last year (YoY), quarterly revenue grew by 22.90%, and quarterly earnings saw a YoY growth of 22.94%.
- How much of INSM stock is held by insiders and institutions?
- Wondering who owns Insmed stock? Company insiders (like executives and directors) hold about 0.75% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.87%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.